These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 28733126

  • 1. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
    Arhin FF, Seguin DL, Belley A, Moeck G.
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):168-171. PubMed ID: 28733126
    [Abstract] [Full Text] [Related]

  • 2. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T, Moeck G.
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [Abstract] [Full Text] [Related]

  • 3. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA.
    Drugs; 2010 May 07; 70(7):859-86. PubMed ID: 20426497
    [Abstract] [Full Text] [Related]

  • 4. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010.
    Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN.
    Antimicrob Agents Chemother; 2012 Mar 07; 56(3):1639-42. PubMed ID: 22183169
    [Abstract] [Full Text] [Related]

  • 5. [Vancomycin-resistant enterococci (VRE). Recent results and trends in development of antibiotic resistance].
    Klare I, Witte W, Wendt C, Werner G.
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Nov 07; 55(11-12):1387-400. PubMed ID: 23114437
    [Abstract] [Full Text] [Related]

  • 6. Molecular characterization of vancomycin-resistant Enterococcus spp. clinical isolates recovered from hospitalized patients among several medical institutions in China.
    Sun H, Wang H, Xu Y, Jones RN, Costello AJ, Liu Y, Li G, Chen M, Mendes RE.
    Diagn Microbiol Infect Dis; 2012 Dec 07; 74(4):399-403. PubMed ID: 23099304
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Belley A, Arhin FF, Moeck G.
    Antimicrob Agents Chemother; 2018 Jan 07; 62(1):. PubMed ID: 29109163
    [Abstract] [Full Text] [Related]

  • 8. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.
    Neudorfer K, Schmidt-Malan SM, Patel R.
    Diagn Microbiol Infect Dis; 2018 Jan 07; 90(1):58-63. PubMed ID: 29195766
    [Abstract] [Full Text] [Related]

  • 9. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
    Rathe M, Kristensen L, Ellermann-Eriksen S, Thomsen MK, Schumacher H.
    APMIS; 2010 Jan 07; 118(1):66-73. PubMed ID: 20041873
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF.
    Int J Antimicrob Agents; 2015 Dec 07; 46(6):674-81. PubMed ID: 26541881
    [Abstract] [Full Text] [Related]

  • 11. Vancomycin resistant enterococci (VRE) still persist in slaughtered poultry in hungary 8 years after the ban on avoparcin.
    Ghidán A, Dobay O, Kaszanyitzky EJ, Samu P, Amyes SG, Nagy K, Rozgonyi F.
    Acta Microbiol Immunol Hung; 2008 Dec 07; 55(4):409-17. PubMed ID: 19130748
    [Abstract] [Full Text] [Related]

  • 12. Characteristics of Vancomycin-Resistant Enterococcus Strains in the West Balkans: A First Report.
    Jakovac S, Bojić EF, Ibrišimović MA, Tutiš B, Ostojić M, Hukić M.
    Microb Drug Resist; 2017 Jan 07; 23(1):122-126. PubMed ID: 27351410
    [Abstract] [Full Text] [Related]

  • 13. Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
    Hill CM, Krause KM, Lewis SR, Blais J, Benton BM, Mammen M, Humphrey PP, Kinana A, Janc JW.
    Antimicrob Agents Chemother; 2010 Jul 07; 54(7):2814-8. PubMed ID: 20404117
    [Abstract] [Full Text] [Related]

  • 14. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.
    Belley A, Lalonde-Séguin D, Arhin FF, Moeck G.
    Antimicrob Agents Chemother; 2017 Oct 07; 61(10):. PubMed ID: 28784674
    [Abstract] [Full Text] [Related]

  • 15. Different VanA Elements in E. faecalis and in E. faecium Suggest at Least Two Origins of Tn1546 Among VRE in a Brazilian Hospital.
    Merlo TP, Dabul AN, Camargo IL.
    Microb Drug Resist; 2015 Jun 07; 21(3):320-8. PubMed ID: 25588068
    [Abstract] [Full Text] [Related]

  • 16. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD.
    Int J Antimicrob Agents; 2007 Aug 07; 30(2):143-9. PubMed ID: 17531446
    [Abstract] [Full Text] [Related]

  • 17. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM, Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Dec 07; 53(4):307-10. PubMed ID: 15922534
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
    Wu T, Meyer K, Harrington AT, Danziger LH, Wenzler E.
    J Antimicrob Chemother; 2019 May 01; 74(5):1300-1305. PubMed ID: 30753495
    [Abstract] [Full Text] [Related]

  • 19. Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
    Tsai HY, Lee YL, Liu PY, Lu MC, Shao PL, Lu PL, Cheng SH, Ko WC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Lee WS, Shi ZY, Chen YS, Wang FD, Tseng SH, Chen YH, Sheng WH, Lee CM, Chen YH, Liao CH, Hsueh PR.
    Int J Antimicrob Agents; 2021 Jul 01; 58(1):106353. PubMed ID: 33961991
    [Abstract] [Full Text] [Related]

  • 20. Selection of a teicoplanin-resistant Enterococcus faecium mutant during an outbreak caused by vancomycin-resistant enterococci with the vanB phenotype.
    Kawalec M, Gniadkowski M, Kedzierska J, Skotnicki A, Fiett J, Hryniewicz W.
    J Clin Microbiol; 2001 Dec 01; 39(12):4274-82. PubMed ID: 11724832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.